Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Genentech.
Management of Patients with Chemotherapy - Induced Nausea and Vomiting
Sally Yowell Barbour, Pharm D, BCOP, CPP
Duke University Hospital
The first 5-HT3 antagonist was approved in 1991 for the management of chemotherapy-induced nausea and vomiting (CINV), leading to moving more chemotherapy regimens to the outpatient setting and improving adherence to treatment. Since then, several 5-HT3 antagonists and NK-1 receptor antagonists have been added to the armamentarium. Despite advances, CINV is often inadequately prevented and/or managed. This learning activity reviews current evidence-based interventions for the prevention and management of CINV, including physiologic mechanisms associated with CINV, strategies to target the pathways involved in CINV, and recommended guidelines.
These CME/CE/CPE accredited activities are jointly provided by
